Azithromycin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cholera

Conditions

Cholera

Trial Timeline

Dec 1, 2002 → May 1, 2004

NCT ID

NCT00229944

About Azithromycin

Azithromycin is a phase 3 stage product being developed by Pfizer for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT00229944. Target conditions include Cholera.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002089	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002309	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002344	Phase 1	Completed	—	—	Bacterial Infections
NCT00002082	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002139	Phase 1	Completed	—	—	Bacterial Infections
NCT00002328	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002085	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002090	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT01919996	Phase 2	Terminated	Dec 1, 2013	Nov 1, 2015	Pharyngitis
NCT00871494	Phase 3	Completed	May 1, 2009	Nov 1, 2010	Pelvic Inflammatory Disease
NCT00809328	Phase 3	Completed	Feb 1, 2009	Mar 1, 2010	Community Acquired Pneumonia (CAP)
NCT00939185	Pre-clinical	Completed	Apr 1, 2007	Jan 1, 2009	Respiratory Tract Infections
NCT00229944	Phase 3	Completed	Dec 1, 2002	May 1, 2004	Cholera
NCT01227395	Pre-clinical	Completed	Jul 1, 2002	Mar 1, 2012	HIV Infection
NCT00599079	Approved	Completed	Feb 1, 1993	May 18, 2017	Mycobacterium Avium Complex Lung Disease

Competing Products

9 competing products in Cholera

See all competitors

Product	Company	Stage	Hype Score
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell	Sanofi	Phase 3	76
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell	Sanofi	Approved	84
Ciprofloxacin	Bayer	Phase 3	74
PXVX0200 + placebo	Bavarian Nordic	Phase 3	74
PXVX0200 + Placebo	Bavarian Nordic	Phase 3	74
VAXCHORA (Cholera Vaccine, Live, Oral)	Bavarian Nordic	Approved	82
PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo	Bavarian Nordic	Phase 3	74
PXVX0200 + Placebo	Bavarian Nordic	Phase 1	30
PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol	Emergent BioSolutions	Phase 2	44

Other Products from Pfizer